August 1, 2012 
Pharmaceutical manufacturers are dealing with massive shifts in their industry – less blockbuster drugs, more generics, emergence of different global markets, a greater payor emphasis on outcomes and adherence, less interaction with sales reps, more use of biologics, and the emerging biosimilar opportunity.
All of that is causing a massive shift in where they invest. In some cases, you’re seeing manufacturers invest in devices (e.g., Sanofi diabetes device) or into education and content at a disease (not drug) level or even in mHealth (e.g., Boehringer and Healthrageous).
With that in mind, I found this Booz & Company survey interesting in highlighting how their shift in spending is changing.
Enabling Healthy Decisions 
No comments yet... Be the first to leave a reply!